drugset / Trial / NCT00908934

AZD9056 Relative Bioavailability Study

NCT00908934

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

The aims of this study are to compare the blood levels achieved with a new formulation of AZD9056 to an existing formulation of AZD9056 used in previous studies.

Timeline

Start
2009-05
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9056 Small molecule 50 mg
Subject AZD9056 Small molecule 400 mg

Indications

No indication recorded.